Combined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
|
|
- Curtis Gibson
- 6 years ago
- Views:
Transcription
1 Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago
2 What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy alone Concurrent beats Induction No apparent role for adding induction or consolidation to concurrent chemoradiotherapy (incl maintenance EGFR inhibition)
3 Induction versus Concomitant Therapy Meta-analysis Hazard ratio (HR) plots: (A) survival, (B) PFS Auperin, A. et al. J Clin Oncol; 28:
4 Induction followed by Concurrent CT/XRT CALGB Design R E G I S T E R A (Standard CT/X) B (Ind CT/X) Paclitaxel 50 mg/m 2 IV/1h/week Carboplatin AUC 2 IV/30 min/wk XRT 6600 cgy (total) Paclitaxel 200 mg/m 2 IV/3h Carboplatin AUC 6 IV/30 min q 21 days for a total of 2 cycles Paclitaxel 50 mg/m 2 IV/1h/week Carboplatin AUC 2 IV/30 min/wk XRT 6600 cgy (total) (d 43)
5 Intent-to-Treat Survival Vokes et al JCO, 2007
6 Consolidation HOG LUN 01-24/USO ChemoRT Cisplatin 50 mg/m 2 IV d 1,8,29,36 Etoposide 50 mg/m 2 IV d 1-5 & Concurrent RT 59.4 Gy (1.8 Gy/fr) 203 Stratification Variables: PS 0-1 vs 2 IIIA vs IIIB CR vs. non-cr Randomize Docetaxel 75 mg/m 2 q 3 wk 3 Observation Hanna et al JCO 26:
7 Overall Survival (ITT) Docetaxel : Median: 21.5 months ( ) 3 year survival rate: 27.2% Observation: Median: 24.1 months ( ) 3 year survival rate: 27.6% P-value: Hanna et al JCO 26:
8 GILT CT-RT Design (1) Radiotherapy - starting day 1 of chemotherapy - 2 Gy/day on weekdays for 6.5 weeks - at least 66 Gy Arm A: Consolidation Chemotherapy + Best Supportive Care -21 0/ Randomisation* CR, PR, SD Cisplatin 80 mg/m 2 D1 D22 Oral Vinorelbine 60 mg/m 2 D1 D8 Oral Vinorelbine 80 mg/m 2 D22 D29 Cisplatin 20 mg/m 2 Screening Oral Vinorelbine 50 mg/m weeks Arm B: Best Supportive Care *stratified according to stage
9 GILT CT-RT Patient Distribution REGISTERED PATIENTS N = 288 Recruitment period: 07/05-05/09 Patients treated with CT-RT (2 cycles) N = 279 (96.9%) N evaluable = 242 (86.7%) Randomised patients N = 201 N evaluable 165 (82.1%) Arm A : CT + BSC (2 cycles) N = 96 N evaluable = 76 Arm B : BSC N = 105 N evaluable = 89
10 GILT CT-RT Drug Delivery and Dose Intensity CT-RT Phase N=279 Consolidation Phase N=188 CT+BSC N=86 BSC N=102 Number of patients by cycle of chemotherapy, N (%) First cycle of phase Second cycle of phase 279 (100%) 255 (91.4%) 86 (100%) 78 (90.7%) 102 (100%) 97 (95.1%) Median number of cycles during phase, N Number of patients with RT alone at cycle 2, N 16 Number of patients with at least 1 delayed dose 37 (13.3%) 26 (30.2%) Number of patients with at least 1 cancelled dose 75 (26.9%) 6 (7.0%) Number of patients with at least 1 dose reduction 8 (2.9%) 22 (25.6%) Median relative dose intensity of NVBo, % (range) Median relative dose intensity of CDDP, % (range) 94.1% ( ) 98.5% ( ) 93.3% ( ) 96.5% ( )
11 GILT CT-RT Progression Free and Overall Survival (ITT) Progression-Free Survival Overall Survival ARM A= CT+BSC ARM B= BSC ARM A= CT+BSC ARM B= BSC A: CT+BSC B: BSC 6.4 ( ) 5.5 ( ) Median (95% CI) Number of events Number censored A: CT+BSC B: BSC 20.8 ( ) 18.5 ( )
12 GILT Conclusions Patient numbers are small (96 vs 105) Oral NVB is not a standard There is a positive trend for DCR Subsets of SCCA and stage IIIB of interest What is impact of break times between modalities All other stages of NSCLC are treated with more than 2 cycles
13 Meta-analysis Literature search Yamamoto et al, PASCO 2012 Systematic search using key words (n=1,209) Potentially relevant references identified and screened for retrieval (n=506) Not English-language (n=144), Not phase II or phase III (n=559) Not clinical trials (n=98). Non NSCLC (n=40). Not concurrent chemoradiotherapy (n=26). Not phase II or phase III (n=102). Including Surgery or induction chemotherapy (n=105). No survival endpoint (n=15). Not platinum doublet chemotherapy (n=44). Small study size (n=14). Potentially appropriate trials to be included (n=62) OS did not reach to median (n=3). Including patients with Stage I/II/IV (n=5). Limiting to poor PS, poor risk, or elderly patients (n=8). Excluding patients with progressive diseases after chemoradiotherapy (n=3). Reanalyzed studies which are already included (n=2). 41 studies (7 PIII studies and 34 PII studies) with 45 arms. Without CCT (CCT-): 20 arms (No. of patients: 1,740) With CCT (CCT+): 25 arms (CCCT: 21 arms, SCCT: 4 arms) (No. of patients: 1,707)
14 Factors influencing Survival Median OS (month) Study characteristics Total No. mean SD p Clinical trial Phase II Phase III Chemo regimen CDDP CBDCA Period Region Asian Non-Asian No significant difference was found in the distribution of clinical trial, chemo regimen, period, and region between CCT- and CCT+ (p 0.182).
15 Individual and pooled median OS month CCT- CCT (95%CI: ) 18.5 (95%CI: ) HR= 0.98 (95%CI: ) p= *Adjusted HR= 0.95 (95%CI: ) p= * Adjusted for period and region. I 2 values for assessing heterogeneity were 15.3% in all studies.
16 Subgroup analysis of hazard ratio (Comparison between CCT+ and CCT-) Period Region Asian Non-Asian Hazard ratio (95%CI) 1.15 ( ) 0.96 ( ) 0.91 ( ) 0.84 ( ) 1.01 ( ) p Clinical Trial Phase II Phase III Total 1.03 ( ) 0.94 ( ) 0.98 ( ) Favors CCT+ 1 2 Favors CCT-
17 Yamamoto analysis in Perspective Specific trials (20+25) included in final analysis not specified Quality of individual trials unclear Inclusion of both phase-ii and phase-iii populations Specific patient numbers would be of interest (eg. number of patients in phase-iii trials) Conclusions supported by the larger trials we know: There is no significant effect of consolidation chemotherapy
18 Chemotherapy Matters Dominance of Systemic Failure in CALGB (n = 213) Patients progressed 213 (Vokes et al JCO, 2007) Local Local and distant Distant only Missing data Distant relapses 170 Brain and other 30 Brain only 31 Distant, but not brain 109
19 Wang, L et al. Lung Cancer, 77(1): 89-96, 2012 IS there an Optimal Regimen? Carbo-tax-XRT v Cis-etopo-XRT
20 Overall survival and the progression-free survival curves Wang, L et al. Lung Cancer, 77(1): 89-96, 2012
21 CALGB 9431, 9534 Survival Months from Randomization Arm 1: Gemcitabine/Cisplatin(9431) Arm 2: Paclitaxel/Cisplatin(9431) Arm 3: Vinorelbine/Cisplatin(9431) Arm 4: Paclitaxel/Carboplatin(9534)
22 Pemetrexed-Cisplatin-XRT Phase I Trial Pemetrexed 500 mg/m 2 and carboplatin AUC 5 or 6 can be administered with concurrent chest radiotherapy No major enhancement of in-field toxicity Pemetrexed/carboplatin based CRT allows administration of systemically active doses Examination in a larger Phase II trial is warranted: CALGB Seiwert et al, Clin Cancer Res 2007, 13: 515
23 Optimal chemoradiotherapy platform Cis or carbo with Pemetrexed CALGB (PI: R. Govindan) Carboplatin AUC 5 q3wk Pemetrexed 500/mg² q3wk x 4 XRT 70 Gy Carboplatin AUC 5 q3wk Pemetrexed 500/mg² q3 wk x 4 XRT 70 Gy Cetuximab 400mg/m² loading and 250mg/m² weekly Pemetrexed 500/mg² q3week x 4
24 Probability CALGB Overall Survival CALGB 30407: Overall Survival Arm A (N=48) Arm B (N=51) p-value=0.779 Median Overall Survival Arm A Arm B 21.2 months (95% CI: 7.4-NA) 22.4 months (95% CI: 13-NA) 18 Month Overall Survival Arm A 56% (95% CI 43-74) Arm B 51% (95% CI 38-68) Survival Time (Months) Median follow up: 23 months (as of ) H0: p 0.35 versus H1: p 0.55 p = survival probability at 18 months registration
25 Phase II Study Design Cisplatin 75 mg/m 2 q 3 weeks for 3 cycles with Pemetrexed 500 mg/m 2 q 3 weeks XRT 66 Gy Consolidation with docetaxel N=28 MST: 34 months Gadgeel et al: JTO, 2011
26 Phase I Dose escalation schema Dose level Pemetrexed Cisplatin Concurrent chemotherapy/radiotherapy phase mg/m2 Days 1 and mg/m2 Days 1 3 and Days mg/m2 Days 1 and mg/m2 days 1 3 and Days mg/m2 Days 1 and mg/m2 Days 1 3 and Days mg/m2 Days 1 and mg/m2 Days 1 5 and Days Consolidation chemotherapy phase mg/m2 Day 1, every 21 days 2 cycles 75 mg/m2 Day 1, every 21 days 2 cycles Brade A, et al. Int J Radiat Oncol Biol Phys, June 2, 2010
27 Study Design Choy, Schwartzberg et al, PASCO 2012 Original Key Eligibility Criteria: Stage IIIA/IIIB NSCLC Measurable disease ECOG PS 0-1 No prior chemotherapy No prior surgery All histologies* Randomization Arm A Concurrent Radiation Therapy Total dose: Gy (2 Gy per day, 5 days/week, Days 1~45) Pemetrexed 500 mg/m 2 IV q 21 days 3 Carboplatin AUC 5 IV q 21 days 3 Arm B Concurrent Radiation Therapy Total dose: Gy (2 Gy per day, 5 days/week, Days 1~45) Pemetrexed 500 mg/m 2 IV q 21 days 3 Cisplatin 75 mg/m 2 IV q 21 days 3 Consolidation Chemotherapy Pemetrexed 500 mg/m 2 IV q 21 days 3 Begin 3 weeks after completion of chemoradiation Follow-up * Protocol was amended in October 2008 to exclude squamous histology Abbreviations: AUC=area under the curve; IV=intravenous; q=every.
28 Overall Survival CI = confidence interval; NA = not assessable/estimable; PC=pemetrexed-/cisplatin; PCb=pemetrexed/carboplatin;
29 Time to Disease Progression
30 Future Directions Non-squamous NSCLC PROCLAIM- Schema A Randomized Phase III Trial R A N D O M I Z E Arm A Arm B Cisplatin 75 mg/m² q3 week x 3 Pemetrexed 500 mg/m² q 3 week x 3 XRT 66 Gy in 33 fractions Cisplatin 50 mg/m² d1, 8 q4 week x 2 cycles Etoposide 50 mg/m² d1-5 q4week x 2 cycles XRT 66 Gy in 33 fractions Primary objective : survival Superiority design 80% Powered to detect Hazard Ratio=0.74- Sample Size 600 Pemetrexed X 4 cycles Platinum based doublets x 2 cycles
31 PROCLAIM Update Accrual over 15 pts/month (578 of 600 pts) DMC meetings q 4 months Continued Accrual Central XRT QA review
32 Targeted Therapies with Combined Modality Therapy NOT STATE OF THE ART (YET)
33 CALGB 30605/RTOG 0972 POOR RISK STAGE III NSCLC (n=76 fully accrued) -IIIA/B - PS 2 - PS Wt loss 10% R E G I S T E R Carboplatin AUC 5 D1 Albumin-bound paclitaxel 100/m 2 D1 and 8 every 21 days x 2 cycles Erlotinib 150 mg/day (no maintenance) concomitant with XRT (66Gy) CALGB PIs: R. Lilenbaum; P Janne; M. Samuels RTOG PI: Spring Kong
34 RTOG Schema A Randomized Phase III Trial R A N D O M I Z E Carboplatin Paclitaxel XRT 60 Gy in 6 weeks Carboplatin Paclitaxel XRT 74 Gy in 7.5 weeks Carboplatin Paclitaxel Cetuximab XRT 60 Gy in 6 weeks Carboplatin Paclitaxel Cetuximab XRT 74 Gy in 7.5 Carboplatin Paclitaxel Carboplatin Paclitaxel Cetuximab
35 Biomarker Approach Stage III NSCLC For initial exploration avoid concurrent or adjuvant setting (SWOG 0023, BR19; awaiting RADIANT) Explore single agent Induction in selected patients followed by standard chemoradiotherapy Molecular testing done as standard of care (EGFR, ALK)
36 ALLIANCE-RTOG Proposal
37 Hypofractionation Administration of large fractions to carefully defined field Highly cytotoxic but associated with toxicity with conventional radiation Feasible with modern targeting Increases dose intensity and saves time Utilized in early stage setting May allow for better integration with chemotherapy
38 CALGB Schema Phase I: Dose Level 1: 60 Gy; Dose Level 2: 60 Gy; Dose Level 3: 60 Gy; Dose Level 4: 60 Gy 2.22 Gy/fx * 27 fractions 2.50 Gy/fx * 24 fractions 2.73 Gy/fx * 22 fractions 3.00 Gy/fx * 20 fractions Chemotherapy: Concurrent: carboplatin/taxol (AUC=2)/paclitaxel 45 mg/m 2 given weekly on days 1,8,15,22 Consolidation: carboplatin (AUC=6) and paclitaxel 200 mg/m 2 every three weeks * 2 cycles. Phase II Based on Phase I Dose above with same chemotherapy
39 Conclusions Several promising new radiation and systemic approaches are under investigation Improved systemic control will need to be an essential component of more effective therapies Randomized approaches and molecular tumor characterization needed due to stage migration and increased understanding of molecular foundation of NSCLC
Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationCombined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC
Combined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC George R. Blumenschein, Jr., MD Associate Professor of Medicine Department of Thoracic/Head & Neck Medical Oncology The University
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationIs consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer?
Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer? ~A pooled analysis of the literature~ Satomi Yamamoto 1, Kazuyuki
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationWhat is Next for Patients with Stage III Non-Small Cell Lung Cancer?
What is Next for Patients with Stage III Non-Small Cell Lung Cancer? Walter J Curran, Jr, MD Executive Director Winship Cancer Institute of Emory University Atlanta, GA NRG Oncology Group Chairman 1 Stage
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationDebate on stage III NSCLC: The role of systemic therapy
1 Debate on stage III NSCLC: The role of systemic therapy Rolf Stahel University Hospital of Zürich Bucharest, 16.6..2015 2 Stage III disease: The problem of heterogeneity, the risk of distant metastases
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationCooperative Group Update - Japan; JCOG & WJOG -
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine, Yokohama City University Chief, Division of Thoracic Surgery, Respiratory Disease Center
More informationLUNG CANCER. Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology. Best of ASCO, İstanbul
LUNG CANCER Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology Best of ASCO, İstanbul 2012 23.6.2012 Treatment of Metastatic NSCLC EGFR targetted treatments 1st line: EGFR-mutated: Afatinib
More informationENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA
ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA Formigal, 28 de Junio de 2018 CÓMO DEFINÍAMOS EL ESTADIO
More informationCombining chemotherapy and radiotherapy of the chest
How to combine chemotherapy, targeted agents and radiotherapy in locally advanced NSCLC? Dirk De Ruysscher, MD, PhD Radiation Oncologist Professor of Radiation Oncology Leuven Cancer Institute Department
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationThe PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationNRG Oncology Lung Cancer Portfolio 2016
NRG Oncology Lung Cancer Portfolio 2016 Roy Decker, MD PhD Yale Cancer Center Walter J Curran, Jr, MD Winship Cancer Institute of Emory University NRG Oncology Lung Cancer Selected Discussion Stage III
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationRecent Advances in Lung Cancer: Updates from ASCO 2016
Recent Advances in Lung Cancer: Updates from ASCO 2016 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/23/2016
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationThe International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationLung cancer update 2007
Lung cancer update 2007 HARMESH R NAIK, MD. January 24, 2007 Epidemiology (world) Estimated 1.35 million new cases in world in 2002 Estimated 1.179 million deaths in world in 2002 Common cancer diagnosis
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationConcurrent and sequential chemoradiotherapy. P. Van Houtte Department of Radiation Oncology Institut Jules Bordet
Concurrent and sequential chemoradiotherapy and radiotherapy for NSCLC P. Van Houtte Department of Radiation Oncology Institut Jules Bordet RADIOTHERAPY & CHEMOTHERAPY A very old concept «Benzene could
More informationMultidisciplinary interactive session (MIS) pn2: The optimal treatment in Wilfried Ernst Erich Eberhardt
Multidisciplinary interactive session (MIS) pn2: The optimal treatment in 2012 Wilfried Ernst Erich Eberhardt Department of Medicine (Cancer Res.), University Hospital Essen, West German Cancer Centre,
More informationStage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99
Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99 Introduction 1/3 of the total lung cancer cases few patients are cured with single modality
More informationCombined modality treatment for NSCLC with N2 disease
Combined modality treatment for NSCLC with N2 disease Gerry Hanna Senior Lecturer and Consultant in Clinical Oncology Centre for Cancer Research and Cell Biology @gerryhanna E: g.hanna@qub.ac.uk Talk Outline
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationASTRO Andrew J. Hope, M.D.
IGRT for lung cancer; does XRT dose escalation improve outcome? Jeffrey Bradley, M.D. Associate Professor Department of Radiation Oncology Washington University and The Alvin J. Siteman Comprehensive Cancer
More informationThe population of patients with stage III non
GREGORY M.M. VIDETIC, MD, CM, FRCPC Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH Locally advanced non small cell lung cancer: What is the optimal concurrent
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More informationCasi clinici di integrazione multiprofessionale: NSCLC stadio III. Biagio Ricciuti. Scuola di Specializzazione in Oncologia Medica
Casi clinici di integrazione multiprofessionale: NSCLC stadio III Scuola di Specializzazione in Oncologia Medica Università degli Studi di Perugia Outline Standard treatment Open questions Clinical cases
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationSao Paulo, Abril 2014
Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use
More informationAdjuvant radiotherapy for completely resected early stage NSCLC
Adjuvant radiotherapy for completely resected early stage NSCLC ESMO Preceptorship on lung Cancer Manchester March 2018 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique
More information11/21/2009. Early Stage. Stage III. From Mountain: Chest, 1997
Combined odality egimens in Locally dvanced SCLC: Current Status and Future irections Primo. Lara, Jr, Professor of edicine University of California avis Cancer Center arly Stage Stage Five-Year Survival
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationCooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D.
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology Group (JCOG) Chief, Division of Thoracic Surgery, Kanagawa
More informationNEJ, Sendai North East Japan. TCOG, Tokyo Tokyo Clinical Oncology G.
Slide 1 Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology Group (JCOG) Chief, Division of Thoracic Surgery,
More informationSlide 1 Combined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC. Slide 2. Slide 3 Options for Locally Advanced NSCLC
Slide 1 Combined Chemotherapy and adiation Therapy for Locally dvanced SCLC George. Blumenschein, Jr., M ssociate Professor of Medicine epartment of Thoracic/Head & eck Medical Oncology The University
More informationClinical Activity Lung Cancer. Andrea Camerini Ospedale Versilia
Clinical Activity Lung Cancer Andrea Camerini Ospedale Versilia The three main objectives in advanced NSCLC 1. In advanced/metastatic cancer, palliation is often the primary treatment goal 2. Potential
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationAdvances in Chemotherapy for Non-Small Cell Lung Cancer
Advances in Chemotherapy for Non-Small Cell Lung Cancer Evan W. Alley, MD, PhD Clinical Associate Professor Abramson Cancer Center at Penn Presbyterian Lung Cancer: Overview Second most common cancer in
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationERCC-1 1 and response to chemotherapy. Jean-Charles SORIA, MD, PhD Institut Gustave Roussy
ERCC-1 1 and response to chemotherapy 1 Jean-Charles SORIA, MD, PhD Institut Gustave Roussy Cancer and Chemotherapy: the exemple of Lung Cancer 2 50 CT + supportive care 40 Surgery ± CT Patients (%) 30
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationLung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Lung cancer in the elderly D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Incidence and mortality of all cancers and lung cancer in relation to age and gender (US) 120,000
More informationAdjuvant Therapy in NSCLC. Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia
Adjuvant Therapy in NSCLC Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia Agenda What do we expect today from new adjuvant chemotherapy Which data do we have with targeted agents
More informationEstado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationCANCER TREATMENT REGIMENS
CANCER TREATMENT S Lung Cancer The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationStato dell arte del. Antonio ROSSI, MD. Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY
Stato dell arte del trattamento del microcitoma Antonio ROSSI, MD Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY Truly has become small. Last session/day in all meetings One chemo
More informationAllan Price NHS Lothian, Edinburgh, UK
Allan Price NHS Lothian, Edinburgh, UK Radiotherapy Dose Volume Timing Technique PCI Surgery Systemic agents 1 Study Dose Time Induction CT Ann Arbor 65.1-75.6 Gy Duke 73.6-80 Gy RTOG 77.4 Gy 74 Gy 6.5-7.5
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationLaryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation
1 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Prague July 2016 State of the art: Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre Aim to discuss Background The trials
More informationUpper Gastrointestinal. Friday, March 2, :00 p.m. 2:45 p.m.
Upper Gastrointestinal Friday, March 2, 2018 2:00 p.m. 2:45 p.m. Social Q&A Use your phone, tablet, or laptop to Submit questions to speakers and moderators Answer interactive questions / audience response
More informationCécile Le Péchoux Department of Radiation Oncology, Institut Gustave Roussy, Villejuif France Amsterdam 2010
Prophylactic Cranial Irradiation in Lung Cancer Cécile Le Péchoux Department of Radiation Oncology, Institut Gustave Roussy, Villejuif France Amsterdam 2010 Prophylactic cranial irradiation PCI was introduced
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationNeoplasie del laringe Diagnosi e trattamento
Neoplasie del laringe Diagnosi e trattamento Venerdì 22 maggio 2015 Alessandria Trattamenti non chirurgici: Preservazione d organo, malattia localmente avanzata Marco C Merlano A.O. S.Croce e Carle, Ospedale
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationTreatment of advanced NSCLC in the elderly. Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Treatment of advanced NSCLC in the elderly Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) Most cancer patients are aged >65 years Ovary Breast NHL Corpus uteri Leukaemias
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationDose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed
Dose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed Take home message Preliminary data shows CRT technique in NSCLC allows dose escalation to an unprecedented level maintaining cancer
More informationSingle Technology Appraisal (STA)
Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response
More informationThe Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
More informationNeoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck. Mei Tang, MD
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD Head and Neck Cancer Worldwide New cases : 644,000 Cancer deaths: 350,000 About 5% of all cancers Local Recurrence:
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More information